ACXP · Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. entered into a Securities Purchase Agreement dated April 15, 2026, to raise capital through a registered direct offering and a concurrent private placement. The registered offering involves the sale of 816,068 shares of common stock at $3.03 per share and pre-funded warrants to purchase 9,017 shares at $3.029 per share, for aggregate gross proceeds of approximately $2.5 million. The pre-funded warrants have a nominal exercise price of $0.001 per share and are immediately exercisable. The shares and pre-funded warrants are offered pursuant to an effective registration statement on Form S-3 (File No. 333-288595).

Concurrently, in a private placement, the Company agreed to issue Series H common warrants to purchase up to 1,650,170 shares of common stock. These warrants have an exercise price of $2.78 per share, are immediately exercisable, and expire twenty-four months following the effective date of a registration statement registering the resale of the underlying shares. The Series H Warrants and underlying shares were offered pursuant to Section 4(a)(2) of the Securities Act and Rule 506(b). The Company agreed to use commercially reasonable efforts to file a Form S-1 to register the resale of these shares within 60 days.

The agreement includes a 15-day lock-up period restricting the Company from issuing or selling common stock or equivalents, with specific exceptions for at-the-market facilities and equity lines of credit. The Company also agreed to a one-year prohibition on variable rate transactions. H.C. Wainwright & Co., LLC is acting as the exclusive placement agent, receiving a cash fee of 6.0% of gross proceeds plus expense allowances. The closing is expected on or about April 16, 2026. Net proceeds are intended for working capital and general corporate purposes.